PL366565A1 - Modulatory działania receptora jądrowego hormonalnego o budowie cyklicznej skondensowanej - Google Patents

Modulatory działania receptora jądrowego hormonalnego o budowie cyklicznej skondensowanej

Info

Publication number
PL366565A1
PL366565A1 PL01366565A PL36656501A PL366565A1 PL 366565 A1 PL366565 A1 PL 366565A1 PL 01366565 A PL01366565 A PL 01366565A PL 36656501 A PL36656501 A PL 36656501A PL 366565 A1 PL366565 A1 PL 366565A1
Authority
PL
Poland
Prior art keywords
hormone receptor
nuclear hormone
fused cyclic
receptor function
modulators
Prior art date
Application number
PL01366565A
Other languages
English (en)
Inventor
Mark E. Salvati
James Aaron Balog
Weifang Shan
Soren Giese
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL366565A1 publication Critical patent/PL366565A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/655Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL01366565A 2000-06-28 2001-06-20 Modulatory działania receptora jądrowego hormonalnego o budowie cyklicznej skondensowanej PL366565A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21439200P 2000-06-28 2000-06-28
US28443801P 2001-04-18 2001-04-18
US28461701P 2001-04-18 2001-04-18

Publications (1)

Publication Number Publication Date
PL366565A1 true PL366565A1 (pl) 2005-02-07

Family

ID=27395986

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01366565A PL366565A1 (pl) 2000-06-28 2001-06-20 Modulatory działania receptora jądrowego hormonalnego o budowie cyklicznej skondensowanej

Country Status (9)

Country Link
KR (1) KR20030014407A (pl)
CN (1) CN1443187A (pl)
AR (1) AR031709A1 (pl)
CZ (1) CZ20024250A3 (pl)
IL (1) IL152890A0 (pl)
PE (1) PE20030186A1 (pl)
PL (1) PL366565A1 (pl)
TR (1) TR200202702T2 (pl)
UY (1) UY26809A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546451B2 (en) 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EP1954670A4 (en) * 2005-11-28 2011-04-27 Gtx Inc NUCLEAR RECEPTOR BINDING AGENTS
CN102875556B (zh) * 2011-07-12 2016-03-30 天津药明康德新药开发有限公司 (4s)-1-取代-2,5-二氮杂双环[2,2,1]庚烷衍生物及制备方法
CN110184346A (zh) * 2019-07-11 2019-08-30 德阳市人民医院 男性骨质疏松症的诊断标志物

Also Published As

Publication number Publication date
PE20030186A1 (es) 2003-03-23
AR031709A1 (es) 2003-10-01
UY26809A1 (es) 2002-01-31
CZ20024250A3 (cs) 2003-10-15
TR200202702T2 (tr) 2004-12-21
KR20030014407A (ko) 2003-02-17
CN1443187A (zh) 2003-09-17
IL152890A0 (en) 2003-06-24

Similar Documents

Publication Publication Date Title
AU2002359727A8 (en) Fused cyclic modulators of nuclear hormone receptor function
MY138531A (en) Fused heterocyclic succinmide compounds and analogs thereof, modulators of nuclear hormone receptor function
TWI263640B (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2002364082A8 (en) Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
WO2002000653A3 (en) Fused cyclic compounds as modulators of nuclear hormone receptor function
WO2006002102A3 (en) Spirocyclic compounds useful as modulators of nuclear hormone receptor function
MX9700223A (es) Composicion farmaceutica para la liberacion controlada de moguisteina en una suspension liquida.
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
MX9707021A (es) Receptor de il-7.
EP1049459A4 (en) ORAL LIQUID COMPOSITIONS
EP0991618A4 (en) SELECTIVE ANALOGS OF THYROID HORMONES
MY136520A (en) Novel compounds
GB9317104D0 (en) Therapeutic heterocycles
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
PL366565A1 (pl) Modulatory działania receptora jądrowego hormonalnego o budowie cyklicznej skondensowanej
EP1854798A3 (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
MXPA02012015A (es) Ligandos de receptores para integrinas.

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)